热门资讯> 正文
Olema与Novartis就Kisqali乳腺癌联合合作达成协议
2024-12-03 01:07
- Olema Pharmaceuticals (NASDAQ:OLMA) will collaborate with Novartis (NYSE:NVS) on a clinical trial examining a combination of the former's palazestrant in combination with the latter's Kisqali (ribociclib) for first-line ER+/HER2- metastatic breast cancer.
- The agreement includes the Swiss drugmaker providing Kisqali for the upcoming phase 3 OPERA-02 trial that will enroll ~1000 participants. That trial is expected to begin in mid-2025.
- Olema also said it has received $250M in private placement equity. Those funds will allow the biopharma to conduct OPERA-02, a phase 1/2 study of OP-3136, a candidate for breast, prostate and lung cancers, and the ongoing phase 3 OPERA-01 trial, which is examining palazestrant as monotherapy.
- Topline data from OPERA-01 is expected in 2026 and new data from an ongoing phase 1b/2 study of palazestrant + Kisqali will be presented at the San Antonio Breast Cancer Symposium later this month.
More on Olema Pharmaceuticals
- Seeking Alpha’s Quant Rating on Olema Pharmaceuticals
- Historical earnings data for Olema Pharmaceuticals
- Financial information for Olema Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
